FDG-PET/CT useful in evaluating response to melanoma drugs

01/11/2012 | AuntMinnie.com (free registration)

Patients with melanoma who had partial metabolic response to bevacizumab plus ipilimumab, determined through FDG-PET/CT scans, had longer disease-free survival compared with patients who had stable or progressive metabolic disease, according to Dana-Farber Cancer Institute researchers. "While the results are preliminary and further studies are needed, these results suggest both contrast-enhanced CT and FDG-PET may be important imaging biomarkers of efficacy for these therapeutic targets in this clinical setting," said researcher Dr. Pamela DiPiro.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations